Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H31N3O5 |
Molecular Weight | 417.4986 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(O)=O
InChI
InChIKey=HHHKFGXWKKUNCY-FHWLQOOXSA-N
InChI=1S/C22H31N3O5/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28)/t17-,18-,19-/m0/s1
Molecular Formula | C22H31N3O5 |
Molecular Weight | 417.4986 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/1712267Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7700063 | https://www.ncbi.nlm.nih.gov/pubmed/1532534
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1712267
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7700063 | https://www.ncbi.nlm.nih.gov/pubmed/1532534
Cilazapril (Vascace and Dynorm are brand names in a number of European countries) is an angiotensin converting enzyme (ACE; kininase II) inhibitor. It competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Cilazapril is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat. The half-life (30–50 hours) of cilazapril allows for once daily dosing unless the hypertension is severe. Cilazapril is used for the treatment of hypertension, congestive heart failure, post-myocardial infarction, and some other indications. Adverse events were mostly observed within the first 8-16 weeks of treatment, with headache, dizziness, fatigue, nausea, cough and chest pain being the most frequent.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1808 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8869081 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Vascace Approved UseVascace is used to treat the following: - High blood pressure (hypertension) - Chronic (long-term) heart failure.
It works by making your blood vessels relax and widen. This helps to lower your blood pressure. It also makes it easier for your heart to pump blood around your body if you have chronic heart failure. |
|||
Primary | Vascace Approved UseVascace is used to treat the following: - High blood pressure (hypertension) - Chronic (long-term) heart failure.
It works by making your blood vessels relax and widen. This helps to lower your blood pressure. It also makes it easier for your heart to pump blood around your body if you have chronic heart failure. |
PubMed
Title | Date | PubMed |
---|---|---|
Cardiovascular effects of the new angiotensin-converting-enzyme inhibitor, cilazapril, in anesthetized and conscious dogs. | 1986 Jan-Feb |
|
Pharmacokinetic and pharmacodynamic interactions between the ACE inhibitor cilazapril and beta-adrenoceptor antagonist propranolol in healthy subjects and in hypertensive patients. | 1989 |
|
Anti-ischemic effects of cilazapril in patients with both hypertension and angina pectoris. Preliminary report of a pilot study. | 1991 |
|
Doctor, there's a fly in my soup! Angiotensin-converting enzyme inhibitors, endogenous opioids and visual hallucinations. | 2001 Dec |
|
Effects of cilazapril on endothelial function and pulmonary hypertension in patients with congestive heart failure. | 2002 Nov |
Sample Use Guides
Swallow each tablet with a drink of water. It does not matter what time of day you take yablet. However, always take it around the same time. Tablet may be taken before or after a meal.
High blood pressure (hypertension): The usual starting dose for adults is 1 mg per day.
Chronic heart failure: The usual starting dose is 0.5 mg per day.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:02:02 UTC 2023
by
admin
on
Sat Dec 16 17:02:02 UTC 2023
|
Record UNII |
8Q9454114Q
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C09BA08
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
||
|
WHO-VATC |
QC09AA08
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
||
|
WHO-ATC |
C09AA08
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
||
|
WHO-VATC |
QC09BA08
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
||
|
NCI_THESAURUS |
C247
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
56330
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
21102
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | RxNorm | ||
|
D017315
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
CHEMBL515606
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
C76134
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
641
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
5675
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
CILAZAPRIL
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
DB01340
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
8Q9454114Q
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
6459
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
DTXSID1048629
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
m3545
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | Merck Index | ||
|
88768-40-5
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
3698
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
SUB23211
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
SUB06265MIG
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SOLVATE->ANHYDROUS | |||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|